Compare Stocks → Biden Nomination CANCELED? (From The Freeport Society) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:AVTXNASDAQ:MNPRNASDAQ:PIRSNASDAQ:RDHL Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVTXAvalo Therapeutics$9.59-0.5%$11.87$3.95▼$1,130.40$9.88M1.21462,851 shs64,400 shsMNPRMonopar Therapeutics$0.61-1.2%$0.69$0.27▼$1.75$10.66M1.173.58 million shs39,400 shsPIRSPieris Pharmaceuticals$10.97-2.5%$13.17$10.60▼$80.80$14.48M0.5510,833 shs5,700 shsRDHLRedHill Biopharma$0.47-1.9%$0.48$0.26▼$3.28$14.07M3.47955,347 shs377,900 shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVTXAvalo Therapeutics0.00%-11.61%-17.54%+115.02%-98.82%MNPRMonopar Therapeutics0.00%-9.25%-4.70%+78.05%-34.41%PIRSPieris Pharmaceuticals0.00%-1.61%-5.43%-12.21%-83.26%RDHLRedHill Biopharma0.00%+3.34%+4.78%-13.98%-77.66%The Overlooked Retirement Asset You Probably Don’t Own (Ad)4 out of 5 Americans believe we’re on the brink of a retirement crisis. Luckily, in these unprecedented times, we have an unprecedented solution. Once considered a “fringe” investment, the crypto market is now taking the world by storm.Click here to access the Crypto Retirement Blueprint now.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVTXAvalo Therapeutics0.15 of 5 stars0.04.00.00.00.61.70.0MNPRMonopar Therapeutics2.7417 of 5 stars3.55.00.00.01.41.70.6PIRSPieris Pharmaceuticals1.0482 of 5 stars0.03.00.04.62.10.80.6RDHLRedHill BiopharmaN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVTXAvalo Therapeutics2.50Moderate BuyN/AN/AMNPRMonopar Therapeutics3.00Buy$2.00227.87% UpsidePIRSPieris Pharmaceuticals2.00HoldN/AN/ARDHLRedHill BiopharmaN/AN/AN/AN/ACurrent Analyst RatingsLatest AVTX, RDHL, PIRS, and MNPR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/10/2024MNPRMonopar TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$2.004/16/2024AVTXAvalo TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform4/11/2024MNPRMonopar TherapeuticsJonestradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$2.00(Data available from 5/20/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVTXAvalo Therapeutics$1.92M5.14N/AN/A($108.83) per share-0.09MNPRMonopar TherapeuticsN/AN/AN/AN/A$0.43 per shareN/APIRSPieris Pharmaceuticals$42.81M0.34N/AN/A$21.66 per share0.51RDHLRedHill Biopharma$6.53M2.15$1.32 per share0.36$0.11 per share4.31Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVTXAvalo Therapeutics-$31.54MN/A0.00N/AN/A-1,639.50%-535.83%-54.17%8/1/2024 (Estimated)MNPRMonopar Therapeutics-$8.40M-$0.52N/AN/AN/AN/A-110.42%-86.33%8/8/2024 (Estimated)PIRSPieris Pharmaceuticals-$24.54M-$11.95N/AN/AN/A-39.71%-52.88%-27.85%8/8/2024 (Estimated)RDHLRedHill Biopharma$23.92MN/A0.00∞N/AN/AN/AN/A6/10/2024 (Estimated)Latest AVTX, RDHL, PIRS, and MNPR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/29/2024Q4 2023PIRSPieris PharmaceuticalsN/A-$4.00-$4.00-$0.06N/A$1.30 million3/28/2024Q4 2023MNPRMonopar Therapeutics-$0.17-$0.12+$0.05-$0.12N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVTXAvalo TherapeuticsN/AN/AN/AN/AN/AMNPRMonopar TherapeuticsN/AN/AN/AN/AN/APIRSPieris PharmaceuticalsN/AN/AN/AN/AN/ARDHLRedHill BiopharmaN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVTXAvalo TherapeuticsN/A0.521.82MNPRMonopar TherapeuticsN/A6.214.17PIRSPieris PharmaceuticalsN/A3.243.24RDHLRedHill BiopharmaN/A0.840.61OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVTXAvalo Therapeutics87.06%MNPRMonopar Therapeutics1.83%PIRSPieris Pharmaceuticals40.11%RDHLRedHill Biopharma7.20%Insider OwnershipCompanyInsider OwnershipAVTXAvalo Therapeutics0.20%MNPRMonopar Therapeutics41.60%PIRSPieris Pharmaceuticals8.89%RDHLRedHill Biopharma6.81%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAVTXAvalo Therapeutics191.03 million1.03 millionNot OptionableMNPRMonopar Therapeutics917.48 million10.21 millionNot OptionablePIRSPieris Pharmaceuticals461.32 million1.20 millionOptionableRDHLRedHill Biopharma5329.70 million27.68 millionNo DataAVTX, RDHL, PIRS, and MNPR HeadlinesRecent News About These CompaniesMay 20 at 3:26 AM | americanbankingnews.comRedHill Biopharma (NASDAQ:RDHL) Receives New Coverage from Analysts at StockNews.comMay 17 at 4:29 PM | bovnews.comAre Options A Good Investment Right Now? Redhill Biopharma Ltd. ADR (RDHL) StockMay 12, 2024 | americanbankingnews.comRedHill Biopharma (NASDAQ:RDHL) Now Covered by Analysts at StockNews.comMay 7, 2024 | finanznachrichten.deRedHill Biopharma Ltd.: RedHill Announces New Opaganib Chinese Patent Against Ebola Virus Valid Through 2035May 6, 2024 | prnewswire.comRedHill Announces New Opaganib Chinese Patent Against Ebola Virus Valid Through 2035April 24, 2024 | finance.yahoo.comRedHill Announces First Patient Enrolled in U.S. Government-Supported COVID-19 StudyApril 10, 2024 | finance.yahoo.comRedHill Biopharma Full Year 2023 Earnings: EPS: US$4.00 (vs US$46.29 loss in FY 2022)April 9, 2024 | bizjournals.comRaleigh pharma weighs divesting commercial operationsApril 8, 2024 | finanznachrichten.deRedHill Biopharma Ltd.: RedHill Biopharma Announces Full-Year 2023 Results and Operational HighlightsApril 8, 2024 | finance.yahoo.comRedHill Biopharma Ltd. (2RH0.F)April 8, 2024 | prnewswire.comRedHill Biopharma Announces Full-Year 2023 Results and Operational HighlightsApril 2, 2024 | finance.yahoo.comRedHill Biopharma Announces $1.25 Million Registered Direct Offering at a Premium to Market PriceMarch 11, 2024 | thepharmaletter.comRedHill announces new ten-year patent for TaliciaMarch 11, 2024 | markets.businessinsider.comRedHill Biopharma Receives New Patent For H. Pylori Treatment TaliciaMarch 11, 2024 | finance.yahoo.comRedHill Announces New USPTO Patent Covering Talicia® Through 2034March 5, 2024 | finance.yahoo.comRedHill's Opaganib Selected for Evaluation by BARDA and NIH Countermeasures ProgramsFebruary 20, 2024 | finance.yahoo.comRedHill's Opaganib Protects Against Radiation-Induced Lung Inflammation and Fibrosis - New PublicationFebruary 20, 2024 | prnewswire.comRedHill's Opaganib Protects Against Radiation-Induced Lung Inflammation and Fibrosis - New PublicationFebruary 16, 2024 | barrons.comRedHill Biopharma Ltd. ADRJanuary 26, 2024 | finance.yahoo.comRedHill Biopharma Announces Closing of $8 Million Registered Direct OfferingNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAvalo TherapeuticsNASDAQ:AVTXAvalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation. The company's drug candidates include AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as Crohn's disease; Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome; and AVTX-008, a fully human B and T Lymphocyte Attenuator (BTLA) agonist fusion protein. It also develops AVTX-803, a L-fucose monosaccharide therapy for treatment of Leukocyte Adhesion Deficiency Type II. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.Monopar TherapeuticsNASDAQ:MNPRMonopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.Pieris PharmaceuticalsNASDAQ:PIRSPieris Pharmaceuticals, Inc., a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc.; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies. The company was founded in 2001 and is headquartered in Boston, Massachusetts.RedHill BiopharmaNASDAQ:RDHLRedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.